Brief: Galecto Completes Strategic Review To Focus On Oncology

Damora Therapeutics

07/10/2024 13:48

Oct 7 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO COMPLETES STRATEGIC REVIEW TO FOCUS ON ONCOLOGY
AND
LIVER DISEASE AND ACQUIRES ACUTE MYELOID LEUKEMIA PRECLINICAL
ASSET FROM BRIDGE MEDICINES
    * GALECTO INC - TO FOCUS ON CANCER AND LIVER DISEASE
    * GALECTO INC - ACQUIRES GLOBAL RIGHTS TO BRM-1420 FOR AML
    * GALECTO INC - PLANS TO FILE IND FOR BRM-1420 IN LATE 2025
OR
EARLY 2026
    * GALECTO INC - TO HALT ADVANCEMENT OF GB2064 LOXL-2
INHIBITOR

Source text for Eikon:  ID:nGNX8MYg2h 
Further company coverage:  GLTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))